MPM vs healthy controls | MPM vs other cancers | MPM vs benign asbestos-related diseases | |
---|---|---|---|
Studies (reference numbers) | 21, 22, 24, 28, 30, 31 | 21, 23, 24, 26, 30, 31, 33, 45, 47 | 21, 23, 24, 25, 28, 30, 33, 40 |
Sensitivity (95% CI) | 0.66 (0.61 to 0.71) | 0.60 (0.56 to 0.64) | 0.58 (0.54 to 0.62) |
Heterogeneity* (p value) | 42.46 (<0.001) | 31.33 (<0.001) | 39.91 (<0.001) |
Specificity (95% CI) | 0.97 (0.96 to 0.98) | 0.81 (0.78 to 0.83) | 0.89 (0.86 to 0.91) |
Heterogeneity (p value) | 46.70 (<0.001) | 52.59 (<0.001) | 39.48 (<0.001) |
PLR (95% CI) | 24.07 (4.03 to 143.68) | 2.81 (2.11 to 3.73) | 6.65 (3.69 to 12.00) |
Heterogeneity (p value) | 48.35 (<0.001) | 26.73 (0.001) | 25.91 (0.001) |
NLR (95% CI) | 0.33 (0.22 to 0.50) | 0.52 (0.43 to 0.63) | 0.44 (0.36 to 0.55) |
Heterogeneity (p value) | 32.11 (<0.001) | 25.45 (0.001) | 24.89 (0.001) |
DOR (95% CI) | 69.27 (15.67 to 306.21) | 5.62 (3.67 to 8.59) | 18.03 (8.90 to 36.52) |
Heterogeneity (p) | 20.80 (0.001) | 22.70 (0.004) | 19.16 (0.008) |
AUC (SEM) | 0.870 (0.120) | 0.734 (0.055) | 0.845 (0.057) |
*Q value.
AUC, area under curve; DOR, diagnostic OR; MPM, malignant pleural mesothelioma; NLR, negative likelihood ratio; PLR, positive likelihood ratio; SMRP, soluble mesothelin-related peptide.